Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB

European Respiratory Journal

Volumn 41, Issue 6, 2013, Pages 1386-1392

  De Lorenzo, Saverio ^a   Alffenaar, Jan Wilem ^f   Sotgiu, Giovanni ^b,c   Centis, Rosella ^d   D'Ambrosio, Lia ^d   Tiberi, Simon ^a   Bolhuis, Mathieu S ^f   Van Altena, Richard ^f   Viggiani, Piero ^a   Piana, Andrea ^b,c   Spanevello, Antonio ^a,e   Migliori, Giovanni Battista ^d  

^a Reference Hospital for MDR and HIV TB   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c AOU Sassari   (Italy)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e UNIVERSITY OF INSUBRIA   (Italy)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Efficacy; Linezolid containing regimens; Meropenem clavulanate; Multidrugresistant tuberculosis; Safety; Tolerability

Indexed keywords

AMIKACIN; CAPREOMYCIN; CLAVULANIC ACID; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; KANAMYCIN; LINEZOLID; MEROPENEM; MEROPENEM PLUS CLAVULANIC ACID; PYRAZINAMIDE; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; ACETAMIDE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; THIENAMYCIN DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BACTERIUM CULTURE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; ITALY; LEUKOPENIA; LIVER FUNCTION TEST; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; OBSERVATIONAL STUDY; OPTIC NEURITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SIDE EFFECT; SPUTUM SMEAR; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; MIDDLE AGED; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ACETAMIDES; ADULT; ANTITUBERCULAR AGENTS; CASE-CONTROL STUDIES; CLAVULANIC ACID; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; THIENAMYCINS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84870747517     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00124312     Document Type: Article

References (26)

1. Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012; 379: 1902-1913.
2. World Health Organization. Global tuberculosis control 2011. WHO/HTM/TB/2011.16. Geneva, WHO, 2011.
3. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015: WHO progress report 2011. Geneva, WHO, 2011.
4. Blasi F, Dara M, Van der Werf MJ, et al. Supporting TB clinicians managing difficult cases: the ERS/WHO Consilium. Eur Respir J 2013; 41: 491-494.
5. Zignol M, van Gemert W, Falzon D, et al. Surveillance of antituberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012; 90: 111-119.
6. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
7. Migliori GB, De Iaco G, Besozzi G, et al. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007; 12: E070517.1.
8. Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug resistant strains in Iran. Chest 2009; 136: 420-425.
9. Udwadia ZF, Amale RA, Ajbani KK, et al. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012; 54: 579-581.
10. Migliori GB, Centis R, D'Ambrosio L, et al. Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease? Clin Infect Dis 2012; 54: 1379-1380.
11. Falzon D, Jaramillo E, Schü nemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
12. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
13. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. The 14-day bactericidal activity of combinations of PA-824, bedaquiline, pyrazinamide and moxifloxacin: the path to novel antituberculosis treatment regimens. Lancet 2012; 380: 986-993.
14. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-393.
15. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
16. Yew WW, Wong CF, Lee J, et al. Do β-lactam-β-lactmase inhibitor combinations have a place in the treatment of multidrug-resistant pulmonary tuberculosis? Tubercle Lung Dis 1995; 78: 90-92.
17. Payen MC, De Wit S, Martin C, et al. Clinical use of meropenem- clavulanate combination for extensively drug-resistant tuberculosis. Int J Tuberc Lund Dis 2012; 16: 558-560.
18. Hugonnet JE, Blanchard JS. Irreversible inhibition of Mycobacterium tuberculosis β-lactamase by clavulanate. Biochemistry 2007; 46: 11198-12004.
19. Hugonnet JE, Tremblay LW, BoshoffHI, et al. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009; 323: 1215-1218.
20. Payen M, Martin C, Antoine-Moussiaux T, et al. Four cases of XDRtuberculosis treated with meropenem-clavulanate. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2010. L1-517. www.abstractsonline.com/Plan/ViewAbstract.aspx? sKey57189a738-03a3-41e0-8ee5- cf36269b5766&cKey5aceae86c-c8ae- 4d8e-968e- d2dd95abed53&mKey5%7b93AEED6A-54D4-4EF6-99BDA9B3CE9FACD9% 7d Date last accessed: April 2, 2013.
21. De Lorenzo S, Centis R, D'Ambrosio L, et al. On linezolid efficacy and tolerability. Eur Respir J 2012; 39: 1-3.
22. Migliori GB, Sotgiu G. Treatment of tuberculosis: have we turned the corner? Lancet 2012; 380: 955-957.
23. Diel R, Rutz S, Castell S, et al. Tuberculosis: cost of illness in Germany. Eur Respir J 2012; 40: 143-151.
24. Loddenkemper R, Sotgiu G, Mitnick CD. Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable? Eur Respir J 2012; 40: 9-11.
25. Raviglione MC, Lange C, Migliori GB. Preventing and managing antimicrobial resistance: an imperative for chest physicians. Eur Respir J 2011; 37: 978-981.
26. Migliori GB, Langendam MW, D'Ambrosio L, et al. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. Eur Respir J 2012; 40: 814-822.